Nateglinide [Inn] en es it fr

Nateglinide [Inn] Brand names, Nateglinide [Inn] Analogs

Nateglinide [Inn] Brand Names Mixture

  • No information avaliable

Nateglinide [Inn] Chemical_Formula


Nateglinide [Inn] RX_link

Nateglinide [Inn] fda sheet

Nateglinide_[Inn] FDA

Nateglinide [Inn] msds (material safety sheet)

Nateglinide [Inn] Synthesis Reference

No information avaliable

Nateglinide [Inn] Molecular Weight

317.423 g/mol

Nateglinide [Inn] Melting Point

No information avaliable

Nateglinide [Inn] H2O Solubility

Practically insoluble

Nateglinide [Inn] State


Nateglinide [Inn] LogP


Nateglinide [Inn] Dosage Forms

Tablets (60, 120 mg)

Nateglinide [Inn] Indication

For use as monotherapy to lower blood glucose in patients with Type 2 diabetes (non-insulin dependent diabetes mellitus, NIDDM) whose hyperglycemia cannot be adequately controlled by diet and physical exercise and who have not been chronically treated with other anti-diabetic agents. Also indicated for use in combination with metformin.

Nateglinide [Inn] Pharmacology

Nateglinide is an amino-acid derivative that lowers blood glucose levels by stimulating insulin secretion from the pancreas. This action is dependent upon functioning beta-cells in the pancreatic islets.

Nateglinide [Inn] Absorption

Rapidly absorbed following oral administration prior to a meal, absolute bioavailability is estimated to be approximately 73%.

Nateglinide [Inn] side effects and Toxicity

An overdose may result in an exaggerated glucose-lowering effect with the development of hypoglycemic symptoms.

Nateglinide [Inn] Patient Information

Nateglinide [Inn] Organisms Affected

Humans and other mammals